person
Angélique V.
- Country
- France
- Department
- Oncology
Research Overview
assignment
32
Clinical Trials ·
- Phase II Study of Durvalumab, Tremelimumab, and Olaparib in Solid Tumors with Homologous Recombination Repair Gene Mutations Post-Olaparib Response
- A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE).
- Efficacy and Safety Evaluation of TTX-030 and Chemotherapy With or Without Budigalimab in Untreated Metastatic Pancreatic Adenocarcinoma
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
174
Sites with multiple studies
Has run more than one trial at 174 of 380 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating various forms of gastrointestinal cancers, with particular emphasis on colorectal cancer and pancreatic adenocarcinoma.
- Metastatic Colorectal Cancer Management
- Pancreatic Cancer Treatment Strategies
- Gastrointestinal Tumor Therapy
Advanced Cancer Treatment
The investigator focuses on treating advanced and metastatic cancers, particularly exploring innovative approaches in biliary tract cancer and gastric adenocarcinoma.
- Metastatic Disease Management
- Esophageal Cancer Treatment
- Hepatocellular Carcinoma Therapy
Immunotherapy Applications
The investigator has significant involvement in immunotherapy treatments, particularly focusing on microsatellite instability and mismatch repair deficiency cancers.
- Checkpoint Inhibitor Therapy
- Combined Immunotherapy Approaches
- Targeted Cancer Treatments
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.